Human Milk Antibodies Against SARS-CoV-2: A Longitudinal Follow-Up Study.
J Hum Lact
; 37(3): 485-491, 2021 08.
Article
in English
| MEDLINE | ID: covidwho-1325271
ABSTRACT
BACKGROUND:
Human milk contains antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) following Coronavirus Disease 2019 (COVID-19). These antibodies may serve as protection against COVID-19 in infants. However, the evolution of these human milk antibodies over time is unclear. RESEARCHAIM:
To elucidate the evolution of immunoglobulin A (IgA) against SARS-CoV-2 in human milk after a SARS-CoV-2 infection.METHODS:
This longitudinal follow-up study included lactating mothers (N = 24) who had participated in the COVID MILK study. To assess the evolution of SARS-CoV-2 antibodies, serum and human milk samples were collected 14-143 days after the onset of clinical symptoms related to COVID-19. Enzyme-Linked ImmunoSorbent Assay was used to detect antibodies against the ectodomain of the SARS-CoV-2 spike protein.RESULTS:
SARS-CoV-2 antibodies remain present up to 5 months (143 days) in human milk after onset of COVID-19 symptoms. Overall, SARS-CoV-2 IgA in human milk seems to gradually decrease over time.CONCLUSION:
Human milk from SARS-CoV-2 convalescent lactating mothers contains specific IgA antibodies against SARS-CoV-2 spike protein up to at least 5 months post-infection. Passive viral immunity can be transferred via human milk and may serve as protection for infants against COVID-19.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
SARS-CoV-2
/
COVID-19
Type of study:
Cohort study
/
Prognostic study
Limits:
Female
/
Humans
/
Infant
Language:
English
Journal:
J Hum Lact
Journal subject:
Nursing
/
Obstetrics
Year:
2021
Document Type:
Article
Affiliation country:
08903344211030171
Similar
MEDLINE
...
LILACS
LIS